Notably, FDA-approved monoclonal antibodies, such as etrolizumab, have been deployed to obstruct CD11a units and ITGB7 (integrin subunit beta 7) in inflammatory diseases such as severe plaque psoriasis, Crohn’s disease or ulcerative colitis, respectively (46, 47). Here, ITGAL is linked to ulcerative colitis.